[18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

#4521

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Aim(s): To evaluate features on baseline and follow-up FDG PET as potential prognostic biomarkers in NABNEC.

Materials and methods: Patients underwent FDG PET/CT at baseline and 9 weeks after commencing chemotherapy. Lesion SUVmax, total metabolic tumour volume (MTV) (SUV4 threshold) and PERCIST response were recorded. The prognostic impact of baseline SUVmax (≤/> median), MTV (≤/> median) on progression-free survival (PFS) and overall survival (OS) were assessed with log-rank tests. Impact of MTV change and PERCIST was assessed at 9-weeks landmark. Baseline DOTATATE PET results will be reported separately.

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,